Immunovant, Inc. - Common Stock — Filings & Documents (NASDAQ:IMVT) — Page 10 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2019

Current report, Q3 FY2019

Immunovant, Inc. current report, Q3 FY2019

Current report, Q2 FY2019

Immunovant, Inc. current report, Q2 FY2019

1
2
3
4
5
6
7
8
9
10

News

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant Stock: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy (IMVT)

Tracking Baker Brothers Portfolio: Q1 2026 Update

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

Immunovant Stock Gains 12.4% in a Month: What's Driving It?

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT)

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV)

These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Immunovant (NASDAQ:IMVT)

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

These Two Biotech Stocks Rocketed — And One Just Broke Out

Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN)

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints